Parkinson’s Disease is the fastest growing neurodegenerative condition in the world. This presentation covers the prevalence of Parkinson’s Disease across different global regions, as well as by age and sex, and includes information about both the economic and personal burden of the illness. It includes infographics about prevalence predictions, direct and indirect costs, and caregiver burden.

This slide deck was developed by Shen-Yang Lim, Neurologist and Professor at the University of Malaya, Kuala Lumpur, Malaysia, in collaboration with Cambridge (a division of Prime, Cambridge, UK).

Index for
slide deck

Introduction

Epidemiology and burden
Epidemiology and burden
file_download Download slide in HQ

Prevalence of Parkinson’s disease

Prevalence of Parkinson’s disease
Prevalence of Parkinson’s disease
file_download Download slide in HQ
Parkinson’s disease is a widespread public health issue
Parkinson’s disease is a widespread public health issue

Although PD is the fastest growing neurodegenerative disorder worldwide,1,6 it is difficult to estimate the total number of people in the world who are affected by PD, as the methods used to collect these data differ between countries.10 In a study published in 2007, the …

file_download Download slide in HQ
Prevalence of Parkinson’s disease – North and South America
Prevalence of Parkinson’s disease – North and South America

Approximately 1 million individuals in the USA are living with PD.1,2 According to data from the Parkinson’s Foundation Parkinson’s prevalence project (PPPP), 1.2  million people will be living with PD in the USA by 2030.1

Interestingly, there are geographic variations se…

file_download Download slide in HQ
Prevalence of Parkinson’s disease – Europe
Prevalence of Parkinson’s disease – Europe

As outlined on the slide, by some estimates the prevalence of PD appears to be higher in Europe than the rest of the world.2 The population in Europe is broadly older than that of the whole world, meaning that the European population may be more vulnerable to diseases whe…

file_download Download slide in HQ
Prevalence of Parkinson’s disease – Africa
Prevalence of Parkinson’s disease – Africa

There appears to be an upward trend in the prevalence of PD in the Middle East and North Africa.1 However, data are scarce; an analysis of the Global Burden of Disease (GBD) surveys 1990–2016 found no data were available for central sub-Saharan Africa, and southern sub-Sa…

file_download Download slide in HQ
Prevalence of Parkinson’s disease – Western Pacific Region and Southeast Asia
Prevalence of Parkinson’s disease – Western Pacific Region and Southeast Asia

As detailed on the slide, the range of different reported prevalence values for PD in the Western Pacific Region and Southeast Asia are lower than those reported in Europe.1,7 Besides variability in methodology between studies, there are other factors that could contribut…

file_download Download slide in HQ
Ethnic variations in Parkinson’s disease
Ethnic variations in Parkinson’s disease

The ethnic variations in PD are thought to be driven by:1

  • biological factors (e.g., genetics, vascular disease, dementia-associated pathology, and other comorbidities)
  • non-biological factors (e.g., healthcare system inequalities, under-reporting of symptoms).

References…

file_download Download slide in HQ
Prevalence of Parkinson’s disease by age
Prevalence of Parkinson’s disease by age

The prevalence of PD increases with advancing age.1 In a meta-analysis of worldwide prevalence data, PD was found to be >40 times more prevalent in populations aged ≥80 years than in those aged 40–49 years.1 Generally, PD is rare in individuals <40 years old.3

Normally, t…

file_download Download slide in HQ
Prevalence of Parkinson’s disease by sex
Prevalence of Parkinson’s disease by sex

Although there is strong evidence to indicate that a person is more likely to develop PD as they become older, the effect of sex is less clear-cut.1

Analysis of worldwide data found generally higher levels of PD in male populations.1,2 However, the differences were only s…

file_download Download slide in HQ
Predictions of the increase in Parkinson’s disease prevalence
Predictions of the increase in Parkinson’s disease prevalence

Life expectancy continues to grow in the world’s rapidly developing low- and middle-income (LMIC) countries.5 As survival rates improve, due to better economic conditions and healthcare, the prevalence of age-related chronic diseases (including PD) is expected to rise acc…

file_download Download slide in HQ
Risk factors associated with Parkinson’s disease
Risk factors associated with Parkinson’s disease

Approximately 85–95% of PD cases are ‘sporadic’ or ‘idiopathic’, meaning that the cause is unknown.5,6 However, the disease is known to cluster in families, with approximately 5–15% of patients reporting a family history of PD.5,6 There are now several well-established PD…

file_download Download slide in HQ

Related content

image Image Graphic showing extracellular, multimerization, and intracellular targets of alpha-synuclein for therapeutic intervention in Parkinson’s disease
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Chart showing progression of functional decline in Parkinson’s disease with different treatment approaches, from symptomatic benefit to disease modification.
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Diagram showing how COMT inhibitors block the conversion of L-DOPA to 3-OMD, enhancing dopamine levels in the synapse in Parkinson’s disease.
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease